DALLAS, April 9, 2010 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring Avanir Pharmaceuticals Inc. (Nasdaq:AVNR). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
The full report is available at: http://www.beaconequity.com/i/AVNR
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
Avanir Pharmaceuticals Inc. (AVNR) engages in the development of therapeutic products for a variety of diseases primarily for the U.S. market. The Company has recently focused its resources to address the central nervous systems and inflammatory diseases markets. Avanir has one compound candidate, Zenvia, in phase III clinical trials. Zenvia is developed to treat pseudobulbar affect (PBA) and diabetic peripheral neuropathic pain (DPN pain). The Company has one commercialized product to treat cold sores, Abreva, marketed in the United States and Canada by GlaxoSmithKline Consumer Healthcare.
In the report, the analyst notes:
"Avanir has one compound candidate, called Zenvia, in phase III clinical trials. Zenvia is developed to treat pseudobulbar affect (PBA) and diabetic peripheral neuropathic pain (DPN pain).
"Diabetes is a major therapeutic segment of the pharmaceutical industry, with global sales totaling more than $17 billion for 2005, up from $4 billion in sales for 1995. The pharmaceutical industry expects anti-diabetic drug therapies to grow to more than $22 billion by 2012 due to a growing population of aged persons.
"If ultimately approved by the U.S. Food and Drug Administration (FDA), the market for Avanir's drug candidate Zenvia could reach $500 million to more than $1 billion at its market saturation. Zenvia is in phase III clinical trials, with the prospects of commercialization reaching approximately 90% following successful completion of this phase of development."
To read the entire report visit: http://www.beaconequity.com/i/AVNR
See what investors are saying about these stocks at penny stock forum.
BeaconEquity.com is one of the industry's largest small-cap report providers striving to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon Equity nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.